WallStSmart

Ke Holdings Inc (BEKE)vsEUDA Health Holdings Limited (EUDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ke Holdings Inc generates 1832743% more annual revenue ($94.58B vs $5.16M). EUDA leads profitability with a 5.2% profit margin vs 3.2%. EUDA trades at a lower P/E of 0.9x. BEKE earns a higher WallStSmart Score of 45/100 (D+).

BEKE

Hold

45

out of 100

Grade: D+

Growth: 4.0Profit: 3.5Value: 7.3Quality: 5.3
Piotroski: 2/9Altman Z: 1.64

EUDA

Hold

36

out of 100

Grade: F

Growth: 5.3Profit: 3.0Value: 8.3Quality: 4.5
Piotroski: 2/9Altman Z: -74.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BEKESignificantly Overvalued (-630.2%)

Margin of Safety

-630.2%

Fair Value

$2.58

Current Price

$15.72

$13.14 premium

UndervaluedFair: $2.58Overvalued
EUDAUndervalued (+68.0%)

Margin of Safety

+68.0%

Fair Value

$2.72

Current Price

$11.47

$8.75 discount

UndervaluedFair: $2.72Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BEKE2 strengths · Avg: 8.0/10
PEG RatioValuation
0.688/10

Growing faster than its price suggests

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EUDA3 strengths · Avg: 10.0/10
P/E RatioValuation
0.9x10/10

Attractively priced relative to earnings

Revenue GrowthGrowth
60.2%10/10

Revenue surging 60.2% year-over-year

Debt/EquityHealth
-0.6210/10

Conservative balance sheet, low leverage

Areas to Watch

BEKE4 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.644/10

Distress zone — elevated risk

Return on EquityProfitability
4.3%3/10

ROE of 4.3% — below average capital efficiency

Profit MarginProfitability
3.2%3/10

3.2% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EUDA4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$692,0703/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
5.2%3/10

5.2% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : BEKE

The strongest argument for BEKE centers on PEG Ratio, Price/Book. PEG of 0.68 suggests the stock is reasonably priced for its growth.

Bull Case : EUDA

The strongest argument for EUDA centers on P/E Ratio, Revenue Growth, Debt/Equity. Revenue growth of 60.2% demonstrates continued momentum.

Bear Case : BEKE

The primary concerns for BEKE are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 40.6x leaves little room for execution misses. Thin 3.2% margins leave little buffer for downturns.

Bear Case : EUDA

The primary concerns for EUDA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

BEKE profiles as a value stock while EUDA is a hypergrowth play — different risk/reward profiles.

EUDA carries more volatility with a beta of -0.12 — expect wider price swings.

EUDA is growing revenue faster at 60.2% — sustainability is the question.

BEKE generates stronger free cash flow (851M), providing more financial flexibility.

Bottom Line

BEKE scores higher overall (45/100 vs 36/100). EUDA offers better value entry with a 68.0% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ke Holdings Inc

REAL ESTATE · REAL ESTATE SERVICES · China

KE Holdings Inc. is involved in the operation of an integrated online and offline platform for housing transactions and services in the People's Republic of China. The company is headquartered in Beijing, China.

EUDA Health Holdings Limited

REAL ESTATE · REAL ESTATE SERVICES · USA

EUDA Health Holdings Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative therapies for rare diseases and unmet medical needs. Utilizing advanced technologies and a dynamic pipeline, the company aims to tackle critical challenges in supportive care and immune modulation. With a strong emphasis on research and development, EUDA is well-positioned to lead healthcare innovation, committed to improving patient outcomes and expanding access to vital medical therapies through its promising clinical programs.

Visit Website →

Want to dig deeper into these stocks?